Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
DKK 0.01
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer's. In addition, it develops an...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Data is available to registered users only
Buy
Sell